Search research articles
Contact Us
Filters
Showing results (311-320 of 377) with videos related to
Page
of 38
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 18, 2024
Differences and Common Ground in <sup>177</sup>Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 15, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
Ida Sonni, Ely R Felker, Andrew T Lenis, et al.
European Urology Open Science
|
June 8, 2026
Progression-free Survival Following Primary Staging with [<sup>18</sup>F]PSMA-1007-PET/ceCT Versus Na[<sup>18</sup>F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial
Karen M Buch-Olsen, Steinbjørn Hansen, Mie H Vilstrup, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2021
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
Justin Ferdinandus, Wolfgang P Fendler, Andrea Farolfi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 20, 2025
Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning
Carlos Vinícius Gomes, Yizhou Chen, Isabel Rauscher, et al.
European Urology
|
July 6, 2023
Diagnostic Performance and Safety of Positron Emission Tomography with <sup>18</sup>F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, et al.
The Journal of Urology
|
June 25, 2019
<sup>68</sup>Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
The Journal of Urology
|
September 17, 2019
Reply by Authors
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Nuklearmedizin. Nuclear Medicine
|
February 6, 2023
[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT]
Ali Afshar-Oromieh, Matthias Eiber, Wolfgang Fendler, et al.
Page
of 38
Search research articles
Search
Showing results (311-320 of 377) with videos related to
Sort By:
Page
of 38
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 18, 2024
Differences and Common Ground in <sup>177</sup>Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 15, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
Ida Sonni, Ely R Felker, Andrew T Lenis, et al.
European Urology Open Science
|
June 8, 2026
Progression-free Survival Following Primary Staging with [<sup>18</sup>F]PSMA-1007-PET/ceCT Versus Na[<sup>18</sup>F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial
Karen M Buch-Olsen, Steinbjørn Hansen, Mie H Vilstrup, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 8, 2021
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study
Justin Ferdinandus, Wolfgang P Fendler, Andrea Farolfi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 20, 2025
Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning
Carlos Vinícius Gomes, Yizhou Chen, Isabel Rauscher, et al.
European Urology
|
July 6, 2023
Diagnostic Performance and Safety of Positron Emission Tomography with <sup>18</sup>F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais, Johannes Czernin, Pan Thin, et al.
The Journal of Urology
|
June 25, 2019
<sup>68</sup>Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
The Journal of Urology
|
September 17, 2019
Reply by Authors
Andrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Nuklearmedizin. Nuclear Medicine
|
February 6, 2023
[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT]
Ali Afshar-Oromieh, Matthias Eiber, Wolfgang Fendler, et al.
Page
of 38